Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. - Bielekova,B.; Catalfamo,M.; Reichert-Scrivner,S. (Proc Natl Acad Sci USA, 2006)